EukairosCell Partners with Invitrocue, Genecast, and Xylonix to Launch Korea’s First IVD Lab for Advanced Cancer Treatment Diagnostics
“This collaboration brings together cutting-edge diagnostic technologies...to deliver highly accurate, real-time cancer tracking and personalized treatment solutions to patients in Korea."
Seoul, South Korea – August 5, 2025 – EukairosCell Co. Ltd., a leading cell therapy developer of NK cell and stem cell therapies for the treatment of cancer and degenerative disorders, has signed a landmark Memorandum of Understanding (MOU) with Invitrocue PTE. LTD., Genecast Co. Ltd., and Xylonix PTE. LTD. to establish Korea’s first In-Vitro Diagnostic (IVD) laboratory for the Real-Time Patient Cancer Adaptive Treatment Program. The signing ceremony took place at G-SAM Integrative Cancer Center, marking a significant step toward revolutionizing personalized cancer care in Greater Metropolitan Seoul.
This collaboration brings together cutting-edge diagnostic technologies—Invitrocue’s Onco-PDO and Genecast’s ADPS—to deliver highly accurate, real-time cancer tracking and personalized treatment solutions. EukairosCell, leveraging its expertise in cell culture and bioanalytics, will serve as the pioneering IVD lab to offer these advanced diagnostics to cancer patients in Korea. Xylonix will provide scientific guidance, research, and patient outreach to ensure the program’s success.
Onco-PDO, a cornerstone of this initiative, enables doctors to test cancer treatments on patient-derived organoids, replicating the patient’s tumor environment in a lab setting. This allows physicians to identify the most effective therapies tailored to individual patients, minimizing trial-and-error and improving treatment outcomes with up to a 94% successful treatment prediction rate, and high response rates even in cancer cases with 1 or 2 prior failed treatments. Recognized as the world’s leading treatment diagnostic solution, Onco-PDO’s efficacy is underscored by its national insurance coverage in Germany, where it has transformed personalized cancer care by providing reliable, data-driven treatment guidance for both doctors and patients. Complementing Onco-PDO, Genecast’s ADPS technology further optimizes clinical treatment outcomes by enabling real-time adjustments to cancer treatments through weekly monitoring of treatment response, drug resistance development, and early relapse detection, ensuring dynamic and precise patient care.
Dr. Dae-Hee LEE, CEO of EukairosCell and Chairman of G SAM Hospital, expressed his enthusiasm: “We are thrilled to bring this breakthrough in cancer treatment diagnostics to Korea, a service already transforming lives and nationally insured in Germany. This partnership positions EukairosCell to deliver hope and advanced care to cancer patients across the nation.”
Dr. KIM Tae-Sik, MD, renowned oncologist and former Director of Research department and Chief Advisor of G-SAM Cancer Hospital for over 20 years, added: “These innovative diagnostics will significantly benefit late-stage cancer patients. I am hopeful that this collaboration will bring real survival improvements and renewed hope to countless patients and their families in Korea.”
The Real-Time Patient Cancer Adaptive Treatment Program is projected to reach approximately 37,783 patients by 2030, covering Greater Seoul. With a 94% treatment accuracy and 0.001% MAF sensitivity, the program aims to integrate Onco-PDO and ADPS results into clinical care, collaborating with other in-Seoul cancer centers and regional hospitals through K-Medi Hub. Future agreements will finalize operational details, with plans to explore cost coverage with the National Health Insurance Service (NHIS) and potential expansion to additional hubs in the southern regions.
About EukairosCell Co. Ltd.
EukairosCell develops immune and stem cell-based cell therapies for treatment of cancer and degenerative disorders. With advanced bioanalytical capabilities, EukairosCell is poised to deliver cutting-edge diagnostics through its new IVD lab. (Korea Registration: 140-81-96045)
About Invitrocue PTE. LTD.
Invitrocue transforms bioanalytics with its Onco-PDO platform, providing real-world drug selection data to guide cancer treatment decisions. It is approved in 5 countries globally including Germany, Singapore, and Hong Kong, with full insurance coverage in Germany. (Singapore UEN: 201224616W)
About Genecast Co. Ltd.
Genecast provides ADPS, a real-time blood-based cancer tracking technology with the highest cancer detection sensitivity in the world, enhancing patient monitoring and treatment outcomes. (Korea Registration: 667-81-00520)
About Xylonix
Xylonix drives innovation by uniting cutting-edge technologies with fast go-to-market strategies. Leading the scientific development of the Real-Time Patient Adaptive Cancer Care Program, it also drives the marketing of innovative products targeting post-pandemic oncology, chronic inflammation, immune deficiencies, and respiratory infections to significantly enhance patient survival and quality of life. (Singapore UEN: 201624318K)
Media Contact:
Invitrocue PTE. LTD.
Email: martind.bach@invitrocue.com
Xylonix PTE. LTD.
Email: g.irving@xylonix.io
For more information, visit: www.invitrocue.com
Disclaimer: This press release is for informational purposes only. Investors should conduct their own due diligence.